We are live on ! Find out more
BCTX

Briacell Therapeutics
BCTX

22 hedge funds and large institutions have $18.1M invested in Briacell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,153% more capital invested

Capital invested by funds: $1.45M → $18.1M (+$16.7M)

467% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 3

175% more funds holding

Funds holding: 8 → 22 (+14)

0.13% more ownership

Funds ownership: 0.04% → 0.18% (+0.13%)

Holders
22
Holders Change
+14
Holders Change %
+175%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$3.33M
2
AC
Armistice Capital
New York
+$2.37M
3
KC
Kepos Capital
New York
+$2.08M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.66M
5
MI
MMCAP International
Cayman Islands
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
-$174K
2
VF
Virtu Financial
New York
-$58K
3
Osaic Holdings
Osaic Holdings
Arizona
-$24.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Altium Capital Management
New York
$4.27M +$3.33M +5,335 New
AC
2
Armistice Capital
New York
$3.04M +$2.37M +3,802 New
KC
3
Kepos Capital
New York
$2.67M +$2.08M +3,333 New
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$2.13M +$1.66M +2,667 New
CH
5
CVI Holdings
Delaware
$1.71M +$1.33M +2,139 New
M
6
Murchinson
Ontario, Canada
$1.33M +$1.04M +1,667 New
SM
7
Sabby Management
Florida
$1.04M +$149K +239 +22%
RAM
8
Redmond Asset Management
Virginia
$702K – – –
Marshall Wace
9
Marshall Wace
United Kingdom
$337K +$263K +422 New
STA
10
Summit Trail Advisors
New York
$187K +$145K +233 New
Bank of America
11
Bank of America
North Carolina
$119K +$92.9K +149 New
Verition Fund Management
12
Verition Fund Management
Connecticut
$119K +$92.9K +149 New
FIM
13
Freedom Investment Management
Connecticut
$113K +$19.9K +32 +29%
Morgan Stanley
14
Morgan Stanley
New York
$97K +$76K +122 New
Two Sigma Advisers
15
Two Sigma Advisers
New York
$90K +$70.4K +113 New
UBS Group
16
UBS Group
Switzerland
$71K +$53K +85 +2,125%
Goldman Sachs
17
Goldman Sachs
New York
$59K +$46.1K +74 New
ASN
18
Advisory Services Network
Georgia
$24K +$18.7K +30 New
TRCT
19
Tower Research Capital (TRC)
New York
$18K +$13.7K +22 New
Toronto Dominion Bank
20
Toronto Dominion Bank
Ontario, Canada
$5K +$3.74K +6 New
MI
21
MMCAP International
Cayman Islands
$2.13K +$1.66M +2,667 New
HI
22
Harbour Investments
Wisconsin
$1K – – –
ZCA
23
Zeke Capital Advisors
Pennsylvania
– -$174K -300 Closed
VF
24
Virtu Financial
New York
– -$58K -101 Closed
Osaic Holdings
25
Osaic Holdings
Arizona
– -$24.9K -40 Closed

BCTX Hedge Fund Activity: Q2 2021 in Review

22 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2021, worth a combined $18.1M — up 1,153% from $1.45M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BCTX positions and 3 closed out — a net gain of 14 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.33M. The largest seller was Zeke Capital Advisors, exiting entirely with an estimated $174K sold.

  • 22 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2021, up from 8 in Q1 2021.
  • Funds reported $18.1M of Briacell Therapeutics stock for Q2 2021, up 1,153% quarter-over-quarter.
  • 17 funds opened new Briacell Therapeutics positions in Q2 2021 and 3 closed out, a net change of +14 holders.
  • The largest Briacell Therapeutics buyer in Q2 2021 was Altium Capital Management, an estimated $3.33M added.
  • The largest Briacell Therapeutics seller in Q2 2021 was Zeke Capital Advisors, an estimated $174K sold.

Based on aggregated 13F filings for Q2 2021.